News

AbbVie: Emraclidine’s Failure Eliminates An Important Growth Driver (NYSE:ABBV)

1 Mins read

This article was written by

ONeil Trader is a former stockbroker turned full-time independent investor. He focuses on finding growth and biotech stocks with significant growth potential and calculates ideas in large part based on best risk-adjusted returns.

He leads the investing group Growth Stock Forum which features: a model portfolio of 15-20 names updated regularly, a top picks list of up to 10 stocks that are expected to perform well in the current calendar year, trading ideas that target both short-term and medium-term moves, and chat with community dialogue and for questions. Learn More.

Analyst’s Disclosure: I/we have a beneficial long position in the shares of NBIX either through stock ownership, options, or other derivatives. I wrote this article myself, and it expresses my own opinions. I am not receiving compensation for it (other than from Seeking Alpha). I have no business relationship with any company whose stock is mentioned in this article.

This article reflects the author’s opinion and should not be regarded as a buy or sell recommendation or investment advice in any way.

Seeking Alpha’s Disclosure: Past performance is no guarantee of future results. No recommendation or advice is being given as to whether any investment is suitable for a particular investor. Any views or opinions expressed above may not reflect those of Seeking Alpha as a whole. Seeking Alpha is not a licensed securities dealer, broker or US investment adviser or investment bank. Our analysts are third party authors that include both professional investors and individual investors who may not be licensed or certified by any institute or regulatory body.

Read the full article here

Related posts
News

Lucid Group Stock: Not Right EV Stock To Bank On, Not Fit For Mass Market (NASDAQ:LCID)

1 Mins read
This article was written by Follow With combined experience of covering technology companies on Wall Street and working in Silicon Valley, and…
News

Morgan Stanley: Some Of The Preferred Shares Still Yield 7% (NYSE:MS)

1 Mins read
This article was written by Follow The Investment Doctor is a financial writer, highlighting European small-caps with a 5-7 year investment horizon….
News

Will Santa Claus Come To Wall Street?

2 Mins read
By Scott Bauer At a Glance When year-to-date market performance is strong, December equity returns are generally higher Many equity markets have…
Get The Latest News

Subscribe to get the top fintech and
finance news and updates.

Leave a Reply

Your email address will not be published. Required fields are marked *